JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

Search

MediciNova Inc

Закрыт

СекторЗдравоохранение

1.22 2.52

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

1.22

Макс.

1.22

Ключевые показатели

By Trading Economics

Доход

-6.1B

-6.1B

Продажи

135K

135K

Рентабельность продаж

-4,563,511.527

Сотрудники

13

EBITDA

-405K

-3.6M

Дивиденды

By Dow Jones

Следующий отчет о доходах

12 нояб. 2025 г.

Рыночная статистика

By TradingEconomics

Рыночная капитализация

-5.4M

60M

Предыдущая цена открытия

-1.3

Предыдущая цена закрытия

1.22

Новостные настроения

By Acuity

20%

80%

31 / 371 Рейтинг в Healthcare

Техническая оценка

By Trading Central

Уверенность

Weak Bearish Evidence

MediciNova Inc График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

24 окт. 2025 г., 18:41 UTC

Отчет

Procter & Gamble to Focus on Innovation, Not Discounts, to Attract Wary Shoppers - 2nd Update

24 окт. 2025 г., 18:31 UTC

Отчет

Correction to Procter & Gamble to Focus on Innovation

24 окт. 2025 г., 16:25 UTC

Главные движущие силы рынка

Obook Shares Rise, Company Secures New Money Transmitter Licenses

24 окт. 2025 г., 21:24 UTC

Обсуждения рынка

Global Forex and Fixed Income Roundup: Market Talk

24 окт. 2025 г., 21:24 UTC

Обсуждения рынка

Moody's Sees France With Increased Risk of Political Dysfunction -- Market Talk

24 окт. 2025 г., 21:07 UTC

Отчет

The Score: Netflix, Amazon.com, Six Flags and More Stocks That Defined the Week -- WSJ

24 окт. 2025 г., 20:58 UTC

Отчет

S&P 500 Climbs to New Record on Strong Earnings -- WSJ

24 окт. 2025 г., 20:50 UTC

Обсуждения рынка

Financial Services Roundup: Market Talk

24 окт. 2025 г., 20:40 UTC

Отчет

Intel Expects Chip Shortages on Better PC Demand. Here's Why AMD Is Winning Too. -- Barrons.com

24 окт. 2025 г., 20:24 UTC

Отчет

General Dyamics Stock Rises on Earnings. Aerospace Was a Standout. -- Barrons.com

24 окт. 2025 г., 20:23 UTC

Отчет

General Dyamics Stock Rises on Earnings. Aerospace Was a Standout. -- Barrons.com

24 окт. 2025 г., 20:13 UTC

Отчет

These Stocks Moved the Most Today: Intel, AMD, Ford, Deckers, Newmont, Nextracker, Booz Allen, Coinbase, and More -- Barrons.com

24 окт. 2025 г., 20:07 UTC

Обсуждения рынка

Different-Cell Imputation Rose Proportionally in September CPI -- Market Talk

24 окт. 2025 г., 19:40 UTC

Обсуждения рынка

Treasury Yields Mixed, Dollar Stronger Ahead of Fed Week -- Market Talk

24 окт. 2025 г., 19:35 UTC

Обсуждения рынка

Oil Rally on U.S. Russia Sanctions Loses Steam -- Market Talk

24 окт. 2025 г., 19:33 UTC

Отчет

IBM and Google Are Also Making Moves in Quantum. Don't Count Out the Bigger Players. -- Barrons.com

24 окт. 2025 г., 19:29 UTC

Обсуждения рынка

U.S. Natural Gas Ends Week Higher on Weather Outlook -- Market Talk

24 окт. 2025 г., 18:52 UTC

Отчет

Correction to GM Stock Soars to Record High. Earnings Were So Good, They Helped Ford. -- Barrons.com

24 окт. 2025 г., 18:41 UTC

Отчет

GM Stock Soars to Record High. Earnings Were So Good, They Helped Ford. -- Barrons.com

24 окт. 2025 г., 18:03 UTC

Отчет

Beyond Meat Stock Is on a Wild Ride. Why a Meme Rally Looks Undercooked. -- Barrons.com

24 окт. 2025 г., 18:02 UTC

Отчет

Progressive Stock Got Hit After Earnings. It's Time to Buy One of America's Great Companies. -- Barrons.com

24 окт. 2025 г., 18:00 UTC

Обсуждения рынка

U.S. Oil Rig Count Rises By Two to 420 -- Market Talk

24 окт. 2025 г., 16:57 UTC

Отчет

Ford Stock Has Quadrupled Tesla's Gains. What's Behind Its Meteoric Rise. -- Barrons.com

24 окт. 2025 г., 16:54 UTC

Обсуждения рынка

End to Canada-U.S. Trade Talks Not Seen Shifting Nearterm Outlook -- Market Talk

24 окт. 2025 г., 16:44 UTC

Обсуждения рынка
Отчет

Amazon Retail Looks Strong as Consumer Sentiment Improves -- Market Talk

24 окт. 2025 г., 16:39 UTC

Обсуждения рынка
Отчет

Amazon Sentiment Around AWS Seen as Improving in 3Q -- Market Talk

24 окт. 2025 г., 16:33 UTC

Отчет

These Stocks Are Moving the Most Today: Intel, AMD, Ford, Deckers, Newmont, Nextracker, Booz Allen, Coinbase, and More -- Barrons.com

24 окт. 2025 г., 16:23 UTC

Отчет

These Stocks Are Moving the Most Today: Intel, AMD, Ford, Deckers, Newmont, Nextracker, Booz Allen, Coinbase, and More -- Barrons.com

24 окт. 2025 г., 16:20 UTC

Обсуждения рынка

Financial Services Roundup: Market Talk

24 окт. 2025 г., 16:07 UTC

Отчет

Ford Stock Has Quadrupled Tesla's Gains. What's Behind Its Meteoric Rise. -- Barrons.com

Сравнение c конкурентами

Изменение цены

MediciNova Inc Прогноз

Консенсус по рейтингу

By TipRanks

0 ratings

0

Покупка

0

Удержание

0

Продажа

Техническая оценка

By Trading Central

1.48 / 1.5599Поддержка и Сопротивление

Краткосрочная

Weak Bearish Evidence

Среднесрочная

Weak Bullish Evidence

Долгосрочная

Bearish Evidence

Настроения

By Acuity

31 / 371Рейтинг в Здравоохранение

Новостные настроения

Сильные свидетельства восходящего тренда

Волатильность

Ниже среднего

Объем новостей (RCV)

Ниже среднего

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

$

О компании MediciNova Inc

MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological and other disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction, as well as prevention of acute respiratory distress syndrome, and long COVID. The company's product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic and other diseases, including nonalcoholic fatty liver disease and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers. It has license agreements with Kyorin Pharmaceutical Co., Ltd; Angiogene Pharmaceuticals, Ltd.; and Meiji Seika Kaisha, Ltd. The company was incorporated in 2000 and is headquartered in La Jolla, California.
help-icon Live chat